Scholarlink

Background <p>Diabetic retinopathy (DR) remains a leading cause of vision impairment worldwide, with limited therapeutic options and early detection methods. This study aims to identify novel biomarkers for DR to address the critical need for therapeutic targets.</p> Methods <p>We employed a multi-omics strategy combining scRNA-seq analysis of DR-related immune cell populations with bidirectional MR integrating quantitative trait loci (eQTL)/protein quantitative trait loci (pQTL) data to establish HLA-A’s causal role in DR. Clinical validation utilized Chinese cohort peripheral blood samples (<i>n</i> = 81), complemented by molecular docking and cellular experiments testing resveratrol’s modulation of HLA-A under metabolic stress conditions.</p> Results <p>Bidirectional Mendelian randomization identified HLA-A as a causal risk factor for DR, with consistent evidence from both expression quantitative trait loci (eqtl: OR = 1.121, 95% CI [1.057, 1.19], <i>p</i> = 1.584 × 10<sup>−4</sup>. pqtl: OR = 1.136, 95% CI [1.095, 1.178], <i>p</i> = 1.05 × 10<sup>−11</sup>). Sensitivity analyses showed no evidence of horizontal pleiotropy (<i>p</i> = 0.234) or heterogeneity (<i>p</i> = 0.199). Shared causal variants (PP.H4 &gt; 0.8) emerged from Bayesian colocalization. Clinically, peripheral blood HLA-A mRNA levels were significantly increased in DR patients (HbA1c ≥ 7.5%). Critically, in glucolipotoxic conditions, HLA-A knockdown suppressed pro-inflammatory cytokines in THP-1 cells, while glucolipotoxicity potently upregulated HLA-A expression, which was dose-dependently inhibited by resveratrol.</p> Conclusion <p>This multi-omics study establishes HLA-A as a novel causal factor in DR pathogenesis and reveals resveratrol’s potential therapeutic value through HLA-A modulation, providing new insights for targeted intervention strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HLA-A drives diabetic retinopathy pathogenesis: multi-omics integration reveals resveratrol’s therapeutic potential via immunomodulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Jiaqiong Lin,
  • Fangkeng Liang,
  • Yanxia Liu,
  • Zongrui Shen,
  • Xiaoyong Li

摘要

Background

Diabetic retinopathy (DR) remains a leading cause of vision impairment worldwide, with limited therapeutic options and early detection methods. This study aims to identify novel biomarkers for DR to address the critical need for therapeutic targets.

Methods

We employed a multi-omics strategy combining scRNA-seq analysis of DR-related immune cell populations with bidirectional MR integrating quantitative trait loci (eQTL)/protein quantitative trait loci (pQTL) data to establish HLA-A’s causal role in DR. Clinical validation utilized Chinese cohort peripheral blood samples (n = 81), complemented by molecular docking and cellular experiments testing resveratrol’s modulation of HLA-A under metabolic stress conditions.

Results

Bidirectional Mendelian randomization identified HLA-A as a causal risk factor for DR, with consistent evidence from both expression quantitative trait loci (eqtl: OR = 1.121, 95% CI [1.057, 1.19], p = 1.584 × 10−4. pqtl: OR = 1.136, 95% CI [1.095, 1.178], p = 1.05 × 10−11). Sensitivity analyses showed no evidence of horizontal pleiotropy (p = 0.234) or heterogeneity (p = 0.199). Shared causal variants (PP.H4 > 0.8) emerged from Bayesian colocalization. Clinically, peripheral blood HLA-A mRNA levels were significantly increased in DR patients (HbA1c ≥ 7.5%). Critically, in glucolipotoxic conditions, HLA-A knockdown suppressed pro-inflammatory cytokines in THP-1 cells, while glucolipotoxicity potently upregulated HLA-A expression, which was dose-dependently inhibited by resveratrol.

Conclusion

This multi-omics study establishes HLA-A as a novel causal factor in DR pathogenesis and reveals resveratrol’s potential therapeutic value through HLA-A modulation, providing new insights for targeted intervention strategies.